Targeting angiogenesis for the treatment of sarcoma

Current Opinion in Oncology

Volumn 18, Issue 4, 2006, Pages 354-359

  Balasubramanian, Lakshmi ^a   Evens, Andrew M ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Anti angiogenesis; Sarcoma; Treatment; Vascular endothelial growth factor

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 4 DEDIMETHYLAMINOSANCYCLINE; AE 941; ALITRETINOIN; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANTHRACYCLINE; ANTIAMEBIC AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CILENGITIDE; COMBRETASTATIN; DOXORUBICIN; ENDOSTATIN; FUMAGILLIN; FUMAGILLOL CHLOROACETYLCARBAMATE; IM 862; IMATINIB; MARIMASTAT; NEUTRALIZING ANTIBODY; OXIGENE; PRINOMASTAT; PROTEIN TYROSINE KINASE INHIBITOR; RAZOXANE; REBIMASTAT; RETINOIC ACID; SEMAXANIB; SORAFENIB; SQUALAMINE; SUNITINIB; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN ANTIBODY; VATALANIB; VINCA ALKALOID; ZK 22584;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER THERAPY; CARDIOTOXICITY; CLINICAL TRIAL; COLON CANCER; DEPRESSION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; GASTROINTESTINAL TUMOR; HEADACHE; HUMAN; HYPERLIPIDEMIA; KAPOSI SARCOMA; KIDNEY CARCINOMA; LUNG CANCER; NONHUMAN; OSTEOSARCOMA; PANCREATITIS; PRIORITY JOURNAL; RASH; REVIEW; SARCOMA; SARCOMA CELL; VALIDATION PROCESS; XEROSIS;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN-TYROSINE KINASES; SARCOMA; SARCOMA, KAPOSI; THALIDOMIDE; TRETINOIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33748092028     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000228741.64541.ca     Document Type: Review

References (63)

1. Brecht IB, Treuner J. Soft tissue sarcoma in children and adolescents: experiences of the cooperative Soft Tissue Sarcoma Group Studies (CWS-81-96) [in German]. Handchir Mikrochir Plast Chir 2004; 36:275-281.
2. Jemal A, Murray T, Ward E, et al. Cancer statistics 2005. CA Cancer J Clin 2005; 55:10-30.
3. O'Bryan RM, Baker LH, Gottlieb JE, et al. Dose response evaluation of adriamycin in human neoplasia. Cancer 1977; 39:1940-1948.
4. Antman KH, Ryan L, Elias A, et al. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol 1989; 7:126-131.
5. Antman K, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 1993; 11:1276-1285.
6. Patel SR, et al. Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol 1998; 21:317-321.
7. Edmonson JH, Ryan LM, Blum RH, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993; 11:1269-1275.
8. Verweij J, Lee SM, Ruka W, et al. Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the European organization for research and treatment of cancer soft tissue and bone sarcoma group. J Clin Oncol 2000; 18:2081-2086.
9. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29:15.
10. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88:277-285.
11. Abdollahi A, Hahnfeldt P, Maercker C, et al. Endostatin's antiangiogenic signaling network. Mol Cell 2004; 13:649-663.
12. Kim KJ, Li B, Houck K, et al. The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 1992; 7:53-64.
13. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 2002; 99:11393-11398.
14. Zhu J, Trang P, Kim K, et al. Effective inhibition of Rta expression and lytic replication of Kaposi's sarcoma-associated herpesvirus by human RNase P. Proc Natl Acad Sci U S A 2004; 101:9073-9078.
15. Motzer RJ, Michaelson MD, Redman BG, et al. SU11248, a multi-targeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, demonstrated antitumor activity in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 24:1-8. SU11248, a tyrosine kinase inhibitor of VEGF and PDGF, demonstrated clinical activity as a second-line agent in renal cell carcinoma.
16. Onisto M, Slongo ML, Gregnanin L, et al. Expression and activity of vascular endothelial growth factor and metalloproteinases in alveolar and embryonal rhabdomyosarcoma cell lines. Int J Oncol 2005; 27:791-798.
17. Gee MF, Tsuchida R, Eichler-Jonsson C, et al. Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid. Oncogene 2005; 24:8025-8037. The study presents preclinical data in rhabdomyosarcoma cell lines indicating that autocrine VEGF signaling likely influences its growth and inhibition of VEGF may be effective treatment for rhabdomyosarcoma.
18. Pakos EE, Goussia AC, Tsekeris PG, et al. Expression of vascular endothelial growth factor and its receptor, KDR/Flk-1, in soft tissue sarcomas. Anticancer Res 2005; 25:3591-3596.
19. West CC, Brown NJ, Mangham DC, et al. Microvessel density does not predict outcome in high grade soft tissue sarcoma. Eur J Surg Oncol 2005; 31:1198-2105.
20. Kaya M, Wada T, Kawaguchi S, et al. Increased pre-therapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcoma. Br J Cancer 2002; 86:864-869.
21. Kaya M, Wada T, Akatsuka T, et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res 2000; 6:572-577.
22. Kreuter M, Bieker R, Bielack SS, et al. Prognostic relevance of increased angiogenesis in osteosarcoma. Clin Cancer Res 2004; 10:8531-8537.
23. Dalal S, Berry AM, Cullinane CJ, et al. Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family. Clin Cancer Res 2005; 11:2364-2378.
24. Guan H, Zhou Z, Wang H, et al. A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model. Clin Cancer Res 2005; 11:2662-2669.
25. Yoon SS, Segal NH, Olshen AB, et al. Circulating angiogenic factor levels correlate with extent of disease and risk of recurrence in patients with soft tissue sarcoma. Ann Oncol 2004; 15:1261-1266.
26. National Cancer Institute. Understanding cancer series: angiogenesis. Bethesda: National Cancer Institute; 2006. http://www.cancer.gov/cancertopics/ understandingcancer/angiogenesis. [Accessed 25 January 2006]. National Cancer Institute website that includes a comprehensive review of molecules in the angiogenesis pathway with discussion of early clinical studies.
27. Gasparini G, Longo R, Fanelli M, Teicher BA. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J Clin Oncol 2005; 23:1295-1311. Excellent review of anti-angiogenic agents in translational and early-phase clinical studies.
28. Streit M, Riccardi L, Velasco P, et al. Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis. Proc Natl Acad Sci U S A 1999; 96:14888-14893.
29. Werther K, Christensen IJ, Brunner N, Nielsen HJ. Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma. The Danish RANX05 Colorectal Cancer Study Group. Eur J Surg Oncol 2000; 26:657-662.
30. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342. Pivotal phase III study in metastatic colorectal cancer with bevacizumab added to fluouracil-based combination chemotherapy that resulted in a statistically signifi-cant survival benefit.
31. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23:792-799.
32. Hainsworth JD, Sosman JA, Spigel DR, et al. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 2005; 23:7889-7896.
33. Sandler AB, Gray R, Brahmer J, et al. Randomized phase II/III Trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) Trial - E4599 [abstract]. J Clin Oncol 2005; 16S:LBA4.
34. D'Adamo DR, Anderson SE, Albritton K. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol 2005; 23:7135-7142. Anthracycline-naïve patients with advanced soft tissue sarcoma received doxorubicin and bevacizumab with 12% partial response and 65% stable disease (lasting 4 cycles), although with increased incidence of cardiotoxicity despite routine use of dexrazoxane (6/17 patients with grade 2 or more cardiotoxicity).
35. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341:1565-1571.
36. Krown SE. Therapy of AIDS-associated Kaposi's sarcoma: targeting pathogenetic mechanisms. Hematol Oncol Clin North Am 2003; 17:763-783.
37. D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994; 91:4082-4085.
38. Kumar S, Witzig TE, Rajkumar SV. Thalidomide: current role in the treatment of non-plasma cell malignancies. J Clin Oncol 2004; 22:2477-2488.
39. Vacca A, Scavelli C, Montefusco V, et al. Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. J Clin Oncol 2005; 23:5334-5346. A recent report reviewing the mechanism of thalidomide in multiple myeloma, with attention to its role in altering the function of angiogenic genes.
40. Yi-Shin Kuo D, Timmins P, Blank SV, et al. Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: a brief communication from the New York Phase II consortium. Gynecol Oncol 2006; 100:160-165.
41. Fife K, Howard MR, Gracie F, et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre. Int J STD AIDS 1998; 9:751-755.
42. Little RF, Wyvill KM, Pluda JM, et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol 2000; 18:2593-2602.
43. Aboulafia DM, Norris D, Henry D, et al. 9-Cis-retinoic acid capsules in the treatment of AIDS-related Kaposi sarcoma: results of a phase 2 multicenter clinical trial. Arch Dermatol 2003; 139:178-186.
44. Miles SA, Dezube BJ, Lee JY, et al. Antitumor activity of oral 9-cis-retinoic acid in HIV-associated Kaposi's sarcoma. AIDS 2002; 16:421-429.
45. Bernstein ZP, Chanan-Khan A, Miller KC, et al. A multicenter phase II study of the intravenous administration of liposomal tretinoin in patients with acquired immunodeficiency syndrome-associated Kaposi's sarcoma. Cancer 2002; 95:2555-2561.
46. Patel PH, Chaganti RS, Motzer RJ. Targeted therapy for metastatic renal cell carcinoma. Br J Cancer 2006; 94:614-619.
47. FDA News. FDA approves new treatment for gastrointestinal and kidney cancer. http://www.fda.gov/bbs/topics/news/2006/NEW01302.html. [Accessed 25 February 2006].
48. Demetri GD, van Oosterom AT, Blackstein M, et al. Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST [abstract]. J Clin Oncol 2005; 16S:4000. An American Society of Clinical Oncology presentation of the multi-targeted inhibitor VEGF receptor and PDGF receptor, SI11248 (sunitinib), with clinical activity following failure of imatinib resulting in accelerated approval of the drug by the Food and Drugs Administration. Median time-to-tumor progression for patients treated with sunitinib (sutent) was 27 weeks compared to 6 weeks for patients who were not treated.
49. FDA News. FDA approves new treatment for advanced kidney cancer. http://www.fda.gov/bbs/topics/NEWS/2005/NEW01282.html. [Accessed 25 February 2006].
50. Ratain MJ, Eisen T, Stadler WM, et al. Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol 2005; 23:388 (abstr 4544). In a randomized phase III comparison against placebo in relapsed advanced renal cell carcinoma patients, sorafenib doubled median progression free survival (24 versus 12 weeks).
51. Beeram M, Patnaik A, Rowinsky EK. Raf: a strategic target for therapeutic development against cancer. J Clin Oncol 2005; 23:6771-6790. A review that discusses the structure and diverse functions of Raf, the rationale for targeting Raf, and the current status of small molecules.
52. Heymach JV, Desai J, Manola J, et al. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Clin Cancer Res 2004; 10:5732-5740.
53. Kuenen BC, Tabernero J, Baselga J, et al. Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. Clin Cancer Res 2003; 9:1648-1655.
54. Chand HS, Du X, Ma D, et al. The effect of human tissue factor pathway inhibitor-2 on the growth and metastasis of fibrosarcoma tumors in athymic mice. Blood 2004; 103:1069-1077.
55. Larsson H, Sjoblom T, Dixelius J, et al. Antiangiogenic effects of latent antithrombin through perturbed cell-matrix interactions and apoptosis of endothelial cells. Cancer Res 2000; 60:6723-6729.
56. Alamartine E. Up-to-date epidemiological data and better treatment for Kaposi's sarcoma. Transplantation 2005; 80:1656-1657.
57. Krown SE. Highly active antiretroviral therapy in AIDS-associated Kaposi's sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi's sarcoma. J Clin Oncol 2004; 22:399-402. This commentary discusses the anti-tumor effects of highly active anti-retroviral therapy from agents under study for treatment of Kaposi's sarcoma.
58. Tulpule A, Scadden DT, Espina BM, et al. Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma. J Clin Oncol 2000; 18:716-723.
59. Noy A, Scadden DT, Lee J, et al. Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team. J Clin Oncol 2005; 23:990-998. Despite apparent activity of IM862 in phase I and II clinical studies, there was no clinical activity seen in a blinded, placebo-controlled randomized phase III clinical study. This study underscores the importance of phase III clinical studies.
60. Koon HB, Bubley GJ, Pantanowitz L, et al. Imatinib-induced regression of AIDS-related Kaposi's sarcoma. J Clin Oncol 2005; 23:982-989.
61. Cianfrocca M, Cooley TP, Lee JY, et al. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. J Clin Oncol 2002; 20:153-159.
62. Simonart T, Van Vooren JP, Meuris S. Treatment of Kaposi's sarcoma with human chorionic gonadotropin. Dermatology 2002; 204:330-333.
63. Dezube BJ, Von Roenn JH, Holden-Wiltse J, et al. Fumagillin analog in the treatment of Kaposi's sarcoma: a phase I AIDS Clinical Trial Group study. J Clin Oncol 1998; 16:1444-1449.